Log In
BCIQ
Print this Print this
 

DRM04

  Manage Alerts
Collapse Summary General Information
Company Dermira Inc.
DescriptionTopical anticholinergic agent
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationExcessive sweating
Indication DetailsTreat primary axillary hyperhidrosis; Treat severe primary axillary hyperhidrosis
Regulatory Designation
PartnerMaruho Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$95.0M

$25.0M

$70.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/20/2016

$95.0M

$25.0M

$70.0M

Get a free BioCentury trial today